Aptinyx (Aptinyx) Growth Rank : 0 (As of May. 14, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Aptinyx Growth Rank?

Aptinyx has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Aptinyx Growth Rank Related Terms

Thank you for viewing the detailed overview of Aptinyx's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptinyx (Aptinyx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptinyx Inc (OTCPK:APTX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

909 Davis Street, Suite 600, Evanston, IL, USA, 60201

Website

https://www.aptinyx.com

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.

Executives

Joan W. Miller	director	C/O APTINYX INC., 909 DAVIS ST., SUITE 600, EVANSTON IL 60201
Norbert G Riedel	director, officer: CEO and President	BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Ashish Khanna	officer: CFO and CBO	909 DAVIS STREET, SUITE 600, EVANSTON IL 60201
Robert J. Hombach	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Gilmore Neil O'neill	director	215 FIRST STREET, CAMBRIDGE MA 02142
Bain Capital Life Sciences Investors, Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Rachel E. Sherman	director	909 DAVIS STREET, SUITE 600, EVANSTON IL 60201
Bain Capital Life Sciences Fund, L.p.	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Life Sciences Partners, Lp	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Jeffrey Lawrence Schwartz	10 percent owner	C/O BAIN CAPITAL LIFE SCIENCES, LP, 200 CLARENDON STRERET, BOSTON MA 02116
Bcip Life Sciences Associates, Lp	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Adam Koppel	director	C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Henry O Gosebruch	director	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Patrick G Enright	director, 10 percent owner	CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025